In this way, NLRP3-activated BMDMs promote the proliferation of IFN-γ-producing Th1 cells with anti-leukemic effects and may provide information that will serve as a basis for immunotherapy in AML. This evidence concerns the gene NLRP3 and acute myeloid leukemia.